HL151
Phase 3Small molecule
HL151 is one of 29 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
271 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Kenalog
BBassett Healthcare
Phase 3
Comparator: Statins
Merck & Co.Phase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
Standard Adjuvant ET
Eli LillyPhase 3
Flonase
TevaPhase 3
Ciclesonide HFA
Sumitomo Pharma America, Inc.Phase 3
Asmanex
NovartisPreclinical
HL151
HHanlim Pharm. Co., Ltd.
Phase 3
Veramyst
GSKPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HL151. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHanlim Pharm. Co., Ltd.